STOCK TITAN
  1. Home
  2. Sec-filings
  3. CORT
  4. [Form 4] CORCEPT THERAPEUTICS INC Insider Trading Activity

Corcept officer awarded stock, 72 shares withheld

CORCEPT THERAPEUTICS INC (CORT) reported that Chief Accounting & Technology Officer Joseph Douglas Lyon had several equity compensation-related transactions.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

CORCEPT THERAPEUTICS INC (CORT) reported that Chief Accounting & Technology Officer Joseph Douglas Lyon had several equity compensation-related transactions. On September 1, 2026, he acquired 130 shares of common stock under a purchase plan at $113.38 per share and received an additional 130 shares of restricted stock awards that carry a one-year cliff vesting condition tied to continued beneficial ownership of the purchase-plan shares. On September 2, 2026, 72 shares of common stock were withheld by the company at a price based on the September 1 closing price of $113.38 to satisfy tax withholding obligations from vesting restricted stock units; no Rule 10b5-1 trading plan is reported.

Positive

  • None.

Negative

  • None.
Insider Lyon Joseph Douglas
Role See Remarks
Type Security Shares Price Value
Tax Withholding Common Stock F5, F6, F7 72 $113.38 $8K
Grant/Award Common Stock F1, F2, F3 130 $113.38 $15K
Grant/Award Common Stock F4, F3 130 $0.00 $0.00
Holdings After Transaction: Common Stock — 5,683 shares (Direct)
Footnotes (7)
  1. F1. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.
  2. F2. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
  3. F3. Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  4. F4. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
  5. F5. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
  6. F6. The closing price on September 1, 2026 was used to calculate the withholding obligation.
  7. F7. Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
Purchase-plan shares acquired 130 shares Common stock acquired on September 1, 2026 under a purchase plan
Purchase-plan price per share $113.38 per share Price based on closing price on September 1, 2026
Restricted stock awards granted 130 shares Unvested restricted stock awards granted on September 1, 2026 under the purchase plan
Shares withheld for tax obligations 72 shares Common stock withheld on September 2, 2026 to satisfy tax withholding from RSU vesting
Price used for tax withholding calculation $113.38 per share Closing price on September 1, 2026 used to calculate withholding obligation
Unvested restricted stock from prior grants 1,113 shares Unvested restricted stock awards from 2025–2026 grants included in holdings description
restricted stock awards financial
"Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person"
Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.
restricted stock units financial
"tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Incentive Award Plan financial
"established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026"
An incentive award plan is a formal program that rewards employees, executives, or directors with cash, stock, options, or other pay when the company meets set goals or performance targets. Like a sales commission or a loyalty program that pays out when you hit milestones, it’s designed to align staff behavior with company objectives; investors care because it affects a company’s costs, share count (dilution), leadership incentives, and long-term value creation.
purchase plan financial
"purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan"
tax withholding obligations financial
"withheld by the Issuer in order to satisfy certain tax withholding obligations"

FAQ

What equity transactions did CORT’s chief accounting & technology officer report on this Form 4?
He reported acquiring 130 shares on September 1, 2026 under a purchase plan at $113.38 per share, receiving another 130 shares of restricted stock awards, and having 72 shares withheld on September 2, 2026 to satisfy tax withholding obligations from vesting restricted stock units.

Was there any open-market buying or selling of CORT common stock in this Form 4?
No. The filing shows purchase-plan acquisitions, restricted stock awards, and 72 shares withheld by Corcept Therapeutics to cover tax liabilities. It does not report any open-market purchases or sales of CORT common stock by the officer.

What are the vesting terms for the new restricted stock awards reported for CORT?
The filing states the 130 restricted shares granted under the purchase plan will vest 100% on the one-year anniversary of the grant date, provided the reporting person remains the beneficial owner of the purchase-plan shares through that one-year anniversary.

At what price were the CORT purchase-plan shares and tax-withholding shares valued?
Both the purchase-plan acquisition and the tax-withholding transaction reference a price based on the September 1, 2026 closing price of $113.38 per share, which was used to establish the purchase price and calculate the tax withholding obligation.

Does this CORT Form 4 indicate trades under a Rule 10b5-1 trading plan?
No. The document-level Rule 10b5-1 checkbox is marked false, and the footnotes describe a purchase plan and equity awards but do not state that the reported transactions were executed under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lyon Joseph Douglas
(Last)(First)(Middle)
C/O CORCEPT THERAPEUTICS INCORPORATED
101 REDWOOD SHORES PARKWAY
(Street)
REDWOOD CITY CALIFORNIA 94065
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/01/2026A130(1)A$113.38(2)5,625(3)D
Common Stock09/01/2026A130(4)A$0.005,755(3)D
Common Stock09/02/2026F(5)72D$113.38(6)5,683(7)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.
2. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
3. Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
4. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
5. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
6. The closing price on September 1, 2026 was used to calculate the withholding obligation.
7. Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
Remarks:
Chief Accounting & Technology Officer
/s/ Joseph Douglas Lyon09/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Keep reading

More on CORT

Trending in the feed

Open the live feed